BMO Capital Maintains Outperform on Biogen, Lowers Price Target to $347
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Evan Seigerman has maintained an 'Outperform' rating on Biogen (NASDAQ:BIIB) but lowered the price target from $357 to $347.
July 26, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen's price target has been lowered from $357 to $347 by BMO Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by BMO Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100